Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 2/20 | 0.57 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CDK9 | P50750 | 2/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.54 |
| ▸ | IRAK4 | Q9NWZ3 | 8/20 | 0.53 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.51 |
| ▸ | MET | P08581 | 1/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | MARK3 | P27448 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4578043 | 0.91 | IRAK4 (0.49) | CSNK1DCSNK1G2LCKRIPK1SMN1; SMN2 | |
| SCHEMBL31388529 | 0.88 | RIPK1 (0.60) | CSNK1DCSNK1G2RIPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL31388527 | 0.88 | RIPK1 (0.60) | CSNK1DCSNK1G2RIPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL31388528 | 0.88 | RIPK1 (0.60) | CSNK1DCSNK1G2RIPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL19329479 | 0.83 | RIPK1 (0.63) | CSNK1DCSNK1G2RIPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL28240295 | 0.81 | RIPK1 (0.66) | CSNK1DCSNK1G2RIPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL15584613 | 0.81 | KCNJ1 (0.57) | CSNK1DCSNK1G2RIPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4577384 | 0.81 | LCK (0.61) | LCKSMN1; SMN2ALDH1A1ABL1KDR | |
| SCHEMBL13217181 | 0.80 | ALDH1A1 (0.59) | CSNK1DCSNK1G2SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL31721205 | 0.80 | LCK (0.69) | LCKSMN1; SMN2ALDH1A1ABL1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435744-B2 | Piperidine derivatives as NMDA receptor antagonists | GEDEON RICHTER VEGYESZETI GYAR RT (HU) | 2008-10-14 | — | — | US | disclosed |
| EP-1409477-B1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2008-09-17 | — | — | EP | disclosed |
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | UCB Biopharma SRL (BE) | 2004-08-12 | — | — | US | disclosed |
| EP-1409477-A1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003010159-A1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | GRIN1, GRIN2D, GRIN2C | CSNK1D 233/4885CSNK1G2 719/4885LCK 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.